Clinical Trials

Find a Trial

Trial Summary

Protocol No.WO29636
StatusOPEN TO ACCRUAL
Principal InvestigatorPili, Roberto
ScopeNational
PhasePhase III
Age GroupAdult
Title A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA AFTER SURGICAL RESECTION
DescriptionThis Phase III, open-label, randomized, multicenter study is to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with observation in participants with muscle-invasive urothelial carcinoma (UC) who are at high risk for recurrence following resection. Eligible participants will be randomized by a 1:1 ratio into atezolizumab group or control group.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:

  • 18 years or older
  • Confirmed muscle-invasive Urothelial carcinoma
For a full list of participation criteria, please visit clinicaltrials.gov.
Applicable Disease SitesBladder
Other Urinary
Participating InstitutionsIndiana University (IU)
  • Eskenazi Hospital
  • Indiana University Hospital / IU Simon Cancer Center
Treatment TypeTreatment
ContactMarietta L Moore, RNPhone: 317-274-7477
Pager: 317-312-1102
Email: marlmoor@iupui.edu